Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 96 | 5,516 | 44% |
| 2020 | 77 | 4,582 | 47% |
| 2021 | 74 |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 29% of the cases CMS names in Texas; 52 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 1,233 | 247,310−2.7%/yr | −2.7%/yr | 119.71.0× | 52% | 265,400 in 2030+1.2%/yr |
| ERCP & endoscopic ultrasound |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
| 2024 |
| 6,069 |
| 59% |
| 2025 est. | ≈ 7,210 | – |
| 2026 est. | ≈ 7,710 | – |
| 4,723 |
| 51% |
| 2022 | 84 | 4,983 | 54% |
| 2023 | 92 | 5,519 | 57% |
| 2024 | 98 | 6,069 | 59% |
| 2025 from claims | – | 7,212 6,619–7,631 | 59% |
| 2026 forecast | – | 7,705 6,779–8,891 | 60% |
| 2027 forecast | – | 8,224 7,031–9,801 | 60% |
| 2028 forecast | – | 8,777 7,323–10,747 | 61% |
| 2029 forecast | – | 9,365 7,649–11,744 | 61% |
| 2030 forecast | – | 9,991 8,004–12,804 | 62% |
In 2025, 27% inpatient hospital, 72% hospital outpatient, 0% surgery center.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~7,700 | ~2,000 | ~5,700 |
| 2027 · ~8,200 | ~2,100 | ~6,100 |
| 2028 · ~8,800 | ~2,200 | ~6,500 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 25% (27% in 2025), hospital outpatient about 74% (72% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +4.5%/yr |
| 5.7 |
| 2% |
| 5,930 in 2030+6.8%/yr |
| North Carolina | 56 | 3,414+0.2%/yr | +0.2%/yr | 3.5 | 0% | 4,080 in 2030+3%/yr |
| Georgia | 43 | 2,875+5.7%/yr | +5.7%/yr | 3.4 | 0% | 5,590 in 2030+12%/yr |
| Virginia | 42 | 2,548+1.9%/yr | +1.9%/yr | 2.5 | 0% | 4,620 in 2030+10%/yr |
| Maryland | 33 | 2,509+4.4%/yr | +4.4%/yr | 2.9 | 1% | 3,560 in 2030+6%/yr |
| Kentucky | 40 | 2,343+2.3%/yr | +2.3%/yr | 5.2 | 0% | 4,370 in 2030+11%/yr |
| South Carolina | 29 | 1,874+3.7%/yr | +3.7%/yr | 2.8 | 0% | 3,150 in 2030+9%/yr |
| Mississippi | 20 | 1,240+1.2%/yr | +1.2%/yr | 3.3 | 0% | 1,510 in 2030+3.4%/yr |
| Louisiana | 18 | 1,193+5.7%/yr | +5.7%/yr | 3.0 | 0% | 2,510 in 2030+13%/yr |
| Arkansas | 16 | 1,036−1.8%/yr | −1.8%/yr | 2.8 | 0% | 1,540 in 2030+6.9%/yr |
| Alabama | 19 | 1,031+1.9%/yr | +1.9%/yr | 2.4 | 0% | 1,640 in 2030+8%/yr |
| Oklahoma | 14 | 974+2.6%/yr | +2.6%/yr | 2.0 | 0% | 2,260 in 2030+15%/yr |
| Delaware | 12 | 798+6.5%/yr | +6.5%/yr | 4.7 | 0% | 1,560 in 2030+12%/yr |
| District of Columbia | 7 | 762+4.4%/yr | +4.4%/yr | 12.2 | 0% | 1,250 in 2030+8.6%/yr |
| West Virginia | 4 | 478−5.3%/yr | −5.3%/yr | 2.3 | 0% | 670 in 2030+5.8%/yr |
| 130 |
| 7,585−0.2%/yr |
| −0.2%/yr |
| 3.61.1× |
| 6% |
| 10,200 in 2030+5.1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Capsovision leads with 45% of company spending on these surgeons in 2025, +45 pts on 2024.
In 2025, 26 companies reported engagement with Texas’s surgeons worth $370K in consulting, speaking, meals and travel tied to these products, about $3,773 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.